Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Lipodystrophy news

Show

From To
The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

The 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) heard today that over a 20-year period, people who suffered lipodystrophy (fat redistribution) and

Published
26 October 2016
By
Gus Cairns
Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

Watch TheBody.com's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

Published
24 August 2016
From
The Body
Middle-aged people living with HIV have an increased risk of frailty

Middle-aged people living with HIV have an increased risk of frailty compared with their peers without the virus, Dutch investigators report in AIDS. The association

Published
13 January 2016
By
Michael Carter
Body fat changes and lactic acidosis with HIV medicines: EMA recommends removal of class warnings for several medicines

The European Medicines Agency (EMA) has updated the advice on the risk of body fat changes and lactic acidosis with medicines for the treatment of human immunodeficiency virus (HIV) infection. As a result, HIV medicines will no longer require a warning concerning fat redistribution in their product information, and a number of medicines of the class ‘nucleoside and nucleotide analogues’ will no longer require a warning about lactic acidosis.

Published
26 October 2015
From
European Medicines Agency
Does HIV make you fat? Study connects viral load with fat gains

HIV infection, or inflammatory changes associated with it, may be responsible for fat accumulation and body fat redistribution, rather than HIV drugs, the Conference on Retroviruses and

Published
06 March 2015
By
Gus Cairns
Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

New findings show that people with higher viral loads when starting ART for the first time are more likely to undergo substantial body composition changes, such as an increased amount of fat in the abdominal area (called “central adiposity”), than those who start treatment with a lower viral load (abstract 140).

Published
04 March 2015
From
BETA blog
Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

Published
19 July 2014
From
Eurekalert Medicine & Health
Unusual and rare complication described in San Francisco

Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

Published
09 December 2013
From
CATIE
Liquid Injectable Silicone Effective, Safe for Treating HIV Patients with Facial Lipoatrophy

Research in British Columbia, Canada, indicates that liquid injectable silicone administered properly has potential as a safe, effective, natural feeling treatment for patients with HIV-associated facial lipoatrophy (FLA). The researchers tested liquid injectable silicone because temporary filler treatments were not permanent and could result in high costs.

Published
04 June 2013
From
Healio
Protein Structure Discovery Could Lead to Better Treatments for HIV, Early Aging

Researchers at the University of Virginia School of Medicine have determined the molecular structure of a protein whose mutations have been linked to several early aging diseases, and to side effects of common HIV and AIDS medications.

Published
11 April 2013
From
University of Virginia press release
← First12345...6Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.